Drugs.com - New Drug Approvals

FDA Approves Leqembi (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., January 27, 2025 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher...

Feb 9, 2025 - 22:25
 0
FDA Approves Leqembi (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., January 27, 2025 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher...
Read More

Tags:

Previous Article

Enhertu Approved as First HER2-Directed Therapy for Patients with HER2-Low or HE...

Next Article

FDA Approves Grafapex (treosulfan) Preparative Regimen for Allogeneic Hematopoie...

Related Posts

FDA Approves Lumakras (sotorasib) in Combination with Vectibix (panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer

FDA Approves Lumakras (sotorasib) in Combination with V...

Feb 9, 2025  0

FDA Approves Grafapex (treosulfan) Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

FDA Approves Grafapex (treosulfan) Preparative Regimen ...

Feb 9, 2025  0

FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the Treatment of Cystic Fibrosis

FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivaca...

Feb 9, 2025  0